AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02319980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracranial-intracranial bypass surgery
Description: All participants in this group will undergo combined cerebral revascularization surgery,namely superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis(EDMS)
Study NCT01919112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Anodal tDCS will be administered with swallowing exercises
Study NCT03007758 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open ventral hernia repair
Description: An open retromuscular ventral hernia repair involves an incision through your abdominal wall, most often through a prior surgery scar. The contents of the hernia, which may include intestine or fatty tissue, are returned into the abdominal cavity. The posterior (inner-most) layer of the abdominal wall is separated from the muscle and closed, which closes the abdominal cavity. Mesh is then placed over that closed layer, which is outside of the abdominal cavity, but below the abdominal muscles. The anterior (outer-most) layer of the abdominal wall is then closed over the mesh, which closes the hernia.
Study NCT03007758 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robotic ventral hernia repair
Description: A robotic retromuscular ventral hernia repair involves a similar separation of the layers of the abdominal wall, similar mesh placement, and similar closure of the hernia defect. The surgical robot is a tool that allows your surgeon to place long, narrow instruments through small incisions in order to perform surgery from the inside of your abdomen. Rather than one longer incision in the middle of your abdomen, four to six small incisions, about 1 inch, are made along the outer part of your abdomen between the rib cage and hip.
Study NCT01770587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Insomnia Treatment
Study NCT00548587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E5555
Study NCT00548587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT00548587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01919112 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Anodal tDCS will be administered with swallowing exercises
Study NCT01919112 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Anodal tDCS will be administered with swallowing exercises
Study NCT02358538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Description: oral suspension or capsules
Study NCT02659150 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: tocilizumab
Description: subjects will be treated with 162mg of weekly subcutaneous tocilizumab in an open-label manner, this will be done addition to MTX or monotherapy. On subsequent weeks after the first dose of tocilizumab, subjects will be instructed to inject the full amount of syringe according to the directions provided in the Instructions For Use (IFU).
Study NCT00551863 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IVPT
Description: Violence prevention intervention based on Motivational Interviewing and CBT
Study NCT01824472 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Treatment for sleep apnea
Study NCT01824472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: Treatment for insomnia
Study NCT01824472 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham CPAP
Description: Placebo for sleep apnea
Study NCT01281306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was supplied as tablets in blister cards.
Study NCT01824472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CC
Description: Placebo (sham) for insomnia
Study NCT01824472 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: CC
Description: Placebo (sham) for insomnia
Study NCT03418896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotropin
Description: a single injection of a standard dose
Study NCT01815736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablet administered orally once daily
Study NCT01815736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E/C/F/TDF
Description: 150/150/200/300 mg FDC tablet administered orally once daily
Study NCT04364581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Women will be treated with letrozole (5 mg daily) for 10 days before hysteroscopic intervention
Study NCT04364581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Women will be treated with placebo for 10 days before hysteroscopic intervention
Study NCT02111239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CTA
Description: pelvic/abdominal CTA scan
Study NCT02111239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRA
Description: pelvic/abdominal MRA scan
Study NCT01966666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI-287 2 mg/m2
Description: 2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
Study NCT01966666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI-287 6.3 mg/m2
Description: 6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
Study NCT01966666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI-287 20 mg/m2
Description: 20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
Study NCT01966666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500mL 0.9% sodium chloride.
Study NCT01966666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 500mL 0.9% sodium chloride.
Study NCT01815736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFV/FTC/TDF
Description: 600/200/300 mg FDC tablet administered orally once daily
Study NCT01815736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RTV
Description: 100 mg tablet administered orally once daily
Study NCT01815736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATV
Description: 300 mg capsule administered orally once daily
Study NCT00473863 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Computed Tomographic Angiography
Description: CCTA will be performed
Study NCT04259476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: low dose perioperative ketamine infusion. and its effects on post-operative pain.
Study NCT04259476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: low dose perioperative ketamine infusion. and its effects on post-operative pain.
Study NCT01098591 — intervention group
Intervention type: OTHER
Intervention: cell therapy
Study NCT00195351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tigecycline
Description: every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
Study NCT00195351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone sodium + metronidazole
Description: Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
Study NCT02134379 — intervention group
Intervention type: DEVICE
Intervention: Medtronic ICDs, CRT-Ds, and CRT-Ps
Description: Any Medtronic implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device. Device must have capacity to measure thoracic impedance as described in protocol. This includes the majority of FDA-approved Medtronic devices currently in use.
Study NCT01470976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Goal-directed Resuscitation Therapy (GDT)
Description: * A target value of a cardiac index (CI) greater than 3.0 L/min/m2 will be sought.~* The first step will be fluid resuscitation with 250ml aliquots of Lactated Ringer's solution whenever the CI is lower than 3,0 L/min/m2 and systolic volume index (SVI) is lower than 35ml/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period.~* When the CI is lower than or equal to 3,0L/min/m2 and SVI higher than or equal to 35 ml/m2, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.~* The final step will be red blood transfusion to reach a hematocrit higher than 28%.
Study NCT01470976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard protocol
Description: The control group will be managed by the anesthetic team in the operative room and by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
Study NCT02634515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Julphar Insulin R (soluble human insulin, biosimilar)
Description: investigational insulin, Julphar Insulin R (soluble human insulin)
Study NCT02634515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Huminsulin® Normal (soluble human insulin, reference)
Description: marketed product, Huminsulin® Normal (soluble human insulin
Study NCT02614846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine
Study NCT03914352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: In this group participants were treated with PD-1 antibody (240mg, Intravenous drip infusion, Q14 days) since the15 days after hepatic resection and at the interval of 15 days.
Study NCT03914352 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: In this group enrolled patients were treated with TACE at the30 days after hepatic resection.
Study NCT04435067 — intervention group
Intervention type: GENETIC
Intervention: Analysis of genetic mutations and the gene expression profile of lung metastasis and primary neoplasia
Description: The mutational analysis of the main oncogenes and tumor suppressor genes involved in the genesis and tumor progression will be performed on the genomic DNA extracted from each sample using the Ion Torrent TM Oncomine TM Comprehensive Assay version 3 (OCAv3) kit. This panel includes 161 cancer-related genes and allows the identification of all genomic alterations affecting oncogenes and recurrently altered tumor suppressor genes in solid tumors. The study of gene expression will be carried out using Nanostring Technology using the Pancancer IO 360 TM panel which allows simultaneous analysis for each sample of multiple mRNAs associated with crucial pathways in carcinogenesis and the immunological profile of the tumor, defining its up and down conditions gene regulation.
Study NCT04435067 — intervention group
Intervention type: OTHER
Intervention: Radiomics analysis on TAC imaging at diagnosis of lung metastasis and, if possible, of the primary tumor
Description: This study will be performed using the SPAARC IBSI (International Biomarker Standardization Initiative) compliant software implemented in the MatLab environment (MathWorks, Boston, USA) through several steps: (a) CT imaging retrieval, (b) image segmentation and rendering, (c) feature extraction and (d) qualification/quantification. Approximately 200 radiomics characteristics will be extracted, such as: Morphology, Statistical, Intensity Histogram, Gray Level Co-occurrence Matrix 3D_average, Gray Level Co-occurrence Matrix 3D_combined, Gray Level Run Length 3D_average, Gray Level Run Length 3D_combined, Gray Level Size Zone Matrix 3D, Neighbor Gray Tone Difference Matrix 3D, Gray Level Distance Zone Matrix 3D.
Study NCT01392690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dominique's Handy Tricks
Description: Children assisted to 10 workshops where they learned exercises to control their stress and anxiety.
Study NCT03038724 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Rapid HIV test
Study NCT02818010 — intervention group
Intervention type: OTHER
Intervention: Global Physical Activity Questionnaire
Description: The practice of physical activity is measured by the GPAQ 2 questionnaire (Global Physical Activity Questionnaire) developed by the World Health Organization.
Study NCT02054832 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Glycosade
Study NCT03797443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Four escalating dose levels are planned in order to determine the MTD for Phase II~The dose level for Phase II patients will be determined following completion of the Phase 1b study based on response from 3-6 patients receiving the designated dose level of ascorbic acid.
Study NCT03797443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab paclitaxel
Description: 30 minute IV infusions on days 1 and 8 repeated every 21 days, followed by Cisplatin
Study NCT03058614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEUS
Description: In subjects randomized into the CEUS arm, 2 mL of Lumason will be injected as a single dose via a nephrostomy tube at the time of postoperative renal ultrasound, following by 5 mL of normal saline flush. Subjects will be given up to one additional dose injected in the same fashion as indicated during the imaging study to confirm opacification of the ureter.
Study NCT03058614 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Non-contrast CT scan
Description: The CT scan performed in this study arm is regularly performed to evaluate the kidney and look for residual stones after surgery both at UCSF and around the world. It does not require contrast injection, so risks from contrast allergy or any injection are absent. A low dose protocol will be used, and therefore, subjects will be exposed to a very small amount of ionizing radiation as low as 1-2 mSv if randomized into this arm.
Study NCT03058614 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Capping trial
Description: Subjects who are randomized into this study arm will undergo both nephrostomy tube capping and a low dose non-contrast CT scan on the first day after surgery. Successfully passing a capping trial is defined as the absence of fever, worsened flank pain, and leakage around the nephrostomy tube within 4 hours after capping the tube.
Study NCT04216329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor will be administered orally at an initial dose of 80 mg. The first dose will be given on day 2 of radiation and will thereafter be administered weekly on the second day of weekly radiation on weeks 1, 2, 4, and 5. If this dose level is tolerated, the dose will be escalated to 60 mg twice a week (days 1 and 4) on weeks 1,2,4,5. The third and final dose level will also be 60mg administered twice weekly for 6 weeks starting on days 1 and 4 radiation.
Study NCT01815736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: 200/300 mg tablet administered orally once daily
Study NCT03422601 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immunoscore test
Description: To identify patients with high risk (IS 0-1) of relapse or death under oxaliplatin-based adjuvant therapy.
Study NCT01598571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib 50 mg tablet
Study NCT01598571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib 100 μg \[14C\] R406 intravenous micro tracer dose
Study NCT04095195 — intervention group
Intervention type: RADIATION
Intervention: MRCP
Description: Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription
Study NCT04095195 — intervention group
Intervention type: PROCEDURE
Intervention: Endoultrasonography
Description: Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription
Study NCT04438733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test-anastrozole tablet (Salutas Pharma GmbH)
Description: Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
Study NCT04438733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reference-anastrozole tablet (Arimidex)
Description: Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
Study NCT04410146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SQUID Embolization
Description: Embolization of the Middle Meningeal Artery using the SQUID non-adhesive liquid embolic agent
Study NCT04410146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SQUID Embolization and Surgical Evacuation
Description: Embolization of the Middle Meningeal Artery using the SQUID non-adhesive liquid embolic agent and the surgical evacuation of the sub-dural hematoma
Study NCT04410146 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Evacuation
Description: Surgical evacuation of the sub-dural hematoma
Study NCT04410146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other: Medical Management
Description: Standard
Study NCT01815736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COBI
Description: 150 mg tablet administered orally once daily
Study NCT02392884 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Rehabilitation
Description: Provide cognitive techniques and teach compensatory strategies that subjects can use to help them remember to attend appointments, take their medications regularly, increase attention (conversational and task) and concentration, increase cognitive flexibility, develop better problem-solving skills.
Study NCT00874809 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CGMS with an insulin pump using rapid acting insulin
Description: To determine basal changes subject will wear a CGMS with an insulin pump infusing rapid acting insulin
Study NCT00412451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocriplasmin
Description: Intravitreal injection, single administration
Study NCT00412451 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham intravitreal injection
Study NCT05202496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol 0.25Mcg Cap
Description: After orthodontic levelling and alignment, experimental group subjects are administered one capsule of calcitriol 0.25 mcg on a daily basis during the study period. Also, serum vitamin D levels are monitored at monthly intervals and rate of canine retraction is measured at monthly intervals
Study NCT03797443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60minute IV infusion on days 1 and 8 repeated every 21 days followed by Gemcitabine
Study NCT03797443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 30 minute IV infusion on days 1 and 8 repeated every 21 days
Study NCT03240081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50mcg estradiol cream
Description: Use of study drug nightly applied to vulvar vestibule
Study NCT03240081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100mcg estradiol cream
Description: Use of study drug nightly
Study NCT00648310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine 4 mg
Study NCT00648310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks
Study NCT01843322 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoleak repair procedure (navigation technology )
Study NCT00772395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: 35 mg given once weekly start on 2nd postoperative day for 26 weeks (6 months)
Study NCT00772395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given once weekly start on 2nd postoperative day for 26 weeks (6 months)
Study NCT04216329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will begin on the first day or evening prior of radiation and be administered orally daily at a dose of 75 mg/m\^2 during the radiation treatment. Temozolomide will continue until the completion of radiation and then will be stopped. Beginning 1-month post-radiation therapy (RT), the adjuvant temozolomide will be given per standard of care.
Study NCT04216329 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Generic Radiation therapy (RT)
Description: Radiation therapy (RT) will be administered daily (Monday to Friday)
Study NCT05202496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthodontic treatment
Description: experimental group subjects undergo orthodontic treatment after extraction of premolars